Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery
The system is powered by BrainSense technology, which has received approval from USFDA
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Subscribe To Our Newsletter & Stay Updated
